NCT05987358View on ClinicalTrials.gov

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Biliary Carcinoma
Interventions
DRUG

TQB3454 tablets

TQB3454 is a selective IDH1 mutant enzyme inhibitor.

DRUG

TQB3454 tablets matching placebo

Placebo tablets without active substance.

Trial Locations (6)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100142

Beijing Cancer Hospital, Beijing

200433

Third Affiliated Hospital of Naval Medical University, Shanghai

300181

Tianjin Medical University Cancer Institute & Hospital, Tianjin

730030

Lanzhou University Second Hospital, Lanzhou

063001

Tangshan People's Hospital, Tangshan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY